Xoma Corp said it filed aregistration statement with the Securities and ExchangeCommission covering a proposed public offering of 1.3 mlncommon shares.    Xoma, a biotechnology company which produces monoclonalantibody-based products to treat some forms of cancer, saidproceeds will be used to fund research and product development,human clinical trials and the expansion of manufacturingcapacity and working capital.    It said Dillon Read and Co Inc and Alex Brown and Sons Incwill manage the underwriting. Reuter&#3;